Targeted Oncology20m
FDA Grants Fast Track Designation to Invikafusp Alfa in TMB-H Colorectal Cancer
Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...
Eko Health Appoints Justin Spencer as Chief Financial Officer
Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today ...
Lead and cadmium found in muscle-building protein powders, report says
Protein powders may contain high levels of lead and cadmium, with chocolate-flavored and plant-based products testing at the ...
Trump took on big tobacco before and won. He can win again by targeting smoking. | Opinion
Making America Healthy Again’ is a complicated, messy, and massive undertaking bound to meet resistance. Reducing nicotine in ...
FDA approves Bismarck doctor’s new catheter design
When Dr. Bruce Gardner saw first-hand how much harm a forcefully-pulled catheter can do to a patient, he decided to take ...
FDA revises limit on lead in some baby food; Here’s what to know
The US FDA has issued guidance to limit lead levels in processed baby foods, aiming to reduce exposure by 20%-30%.
Peninsula Daily News17h
VisiDefend Side Effects and Risks: Is It Safe for Long-Term Use?
Maintaining optimal eye health has become more crucial in today’s fast-paced world. With the rise of digital screens and ...
Food Processing18h
FDA Sets Limits on Lead in Certain Baby Foods
The agency inches ‘Closer to Zero’ with 10 ppb and 20 ppb voluntary limits – only for lead, only for foods aimed at children ...
Morning Rush (Video) on MSN23h
FDA Sets Lead Limits for Processed Baby Foods Amid Safety Concerns
In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has recently implemented lead limits for processed baby ...
FDA limits toxic lead in baby food, but Illinois rep says more should be done
The Food and Drug Administration put guidelines in place to curb the amount of lead in baby food, but some like one Illinois ...
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...